Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Genentech Alzheimer's Drug Misses Goals in Studies

July 16, 2014 12:27 pm | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose. Read more...

TOPICS:

Arena Gets U.S. Cannabinoid Receptor Modulator Patent

July 16, 2014 11:14 am | News | Comments

Arena Pharmaceuticals Inc. announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators," by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2). Read more...

TOPICS:

Novartis, Banner Alzheimer's Institute to Study Disease Prevention

July 16, 2014 11:10 am | News | Comments

Novartis announced a collaboration with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease prevention that will determine whether two Novartis investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of AD. Read more...

TOPICS:
Advertisement

Pfizer Posts Positive Phase 3 Results for Hemophilia Drug

July 16, 2014 11:03 am | News | Comments

Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFix Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. Read more...

TOPICS:

Lilly, Immunocore Collaborate on Cancer Immunotherapies

July 16, 2014 10:59 am | News | Comments

Eli Lilly and Company and Immunocore Ltd. announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies using Immunocore's Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer technology. Read more...

TOPICS:

International Conference Advances Alzheimer’s Research

July 16, 2014 10:53 am | News | Comments

Results from four research studies reported as "developing topics" at the Alzheimer's Association International Conference 2014 include significant advances in evidence regarding treatment and early detection of Alzheimer's disease and dementia, as well as new ideas in the basic brain science of dementia that may lead to new diagnostic and treatment targets. Read more...

TOPICS:

Scientists Apply “Game Theory” to Cancer Research

July 16, 2014 10:47 am | News | Comments

Cancer’s no game, but researchers at Johns Hopkins are borrowing ideas from evolutionary game theory to learn how cells cooperate within a tumor to gather energy, so that they can identify the ideal time to disrupt metastatic cancer cell cooperation and make a tumor more vulnerable to anti-cancer drugs. Read more...

TOPICS:

Abbott 2Q Revenue Up

July 16, 2014 10:25 am | by The Associated Press | News | Comments

Abbott Laboratories (ABT) said Wednesday that its second-quarter profit declined 2.1%, hampered by higher taxes. Adjusted profit and revenue topped Wall Street expectations, however, and the company boosted its full-year earnings forecast. Read more...

TOPICS:
Advertisement

Avastin Gets Priority Review for Certain Types of Cervical Cancer

July 15, 2014 3:12 pm | News | Comments

Genentech announced that the FDA has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer. Read more...

TOPICS:

Tamoxifen Gel Effective When Applied to Breast

July 15, 2014 3:08 pm | News | Comments

A breakdown product of tamoxifen, 4-OHT, applied as a gel formulation on the breasts of women with ductal carcinoma in situ (DCIS), was as effective in reducing cell proliferation as oral tamoxifen, with fewer side effects compared with oral tamoxifen, according to a study. Read more...

TOPICS:

FDA Grants Priority Review to New Hep C Combo

July 15, 2014 2:51 pm | News | Comments

Medivir AB announced that the FDA has assigned a Priority Review designation to the supplemental New Drug Application for the use of once-daily Olysio, in combination with sofosbuvir, for 12 weeks treatment of adult patients with genotype 1 chronic hepatitis C. Read more...

TOPICS:

Researchers Alleviate Pulmonary Inflammation Through Targeted Drug Delivery

July 15, 2014 2:43 pm | News | Comments

To date, no medication has been successful at preventing or mitigating the damage caused by pulmonary inflammation. Now, a research team has found that when delivered by a microscopic transporter called a nanocarrier, steroids can access the hard-to-reach lung endothelial cells that need it most and are successful at preventing inflammation in mice. Read more...

TOPICS:

Novartis to Use Google Technology for 'Smart' Contacts

July 15, 2014 2:19 pm | News | Comments

Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease. Read more...                 

TOPICS:

Codexis, GSK Collaborate on Platform Technology

July 15, 2014 11:38 am | News | Comments

Codexis Inc., a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announced the signing of a platform technology license agreement with GlaxoSmithKline under which Codexis granted GSK a license to use Codexis’ proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. Read more...

TOPICS:

Cognitive Impairment Precedes, Predicts Alzheimer's Functional Impairment

July 15, 2014 11:29 am | News | Comments

Eli Lilly announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease, which suggest that cognitive decline experienced by patients is followed by an observable related decline in function, consistent with previously proposed hypotheses. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading